THNR
Amplify Weight Loss Drug & Treatment ETF
Amplify Weight Loss Drug & Treatment ETF seeks to provide investors with exposure to companies involved in the development and commercialization of weight loss drugs and treatments.
Global
EQUITY
Passive
MANAGEMENT STYLE
$ 4.3 M
ASSETS UNDER MGMT
59 bp
EXPENSES
Fund Basics
| Inception date | May 20, 2024 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| NOVO-NORDISK A/S-SPONS ADR | 15.0 % |
| ELI LILLY & CO | 12.0 % |
| REGENERON PHARMACEUTICALS | 6.3 % |
| AMGEN INC | 5.9 % |
| ARROWHEAD PHARMACEUTICALS, INC. | 5.7 % |
| CHUGAI PHARMACEUTICAL CO LTD | 5.5 % |
| INNOVENT BIOLOGICS, INC. | 5.5 % |
| ROCHE HOLDING AG | 5.0 % |
| MERCK & CO. INC. | 4.7 % |
| PFIZER INC | 4.7 % |
Constituent Breakdown
| Number of holdings | 18 |
| Herfindahl-Hirschman Index | 708 |
| Wgt avg mkt cap (mns) | $236,114 |
| Large cap (>$10bn) | 86.5% |
| Mid cap ($2-10bn) | 11.2% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 83.9% |
| Emerging mkts. | 6.7% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 48.1 % |
 |
DENMARK | 17.1 % |
 |
JAPAN | 10.1 % |
 |
HONG KONG | 5.7 % |
 |
CHINA | 5.5 % |
 |
BRITAIN | 4.6 % |
 |
SOUTH KOREA | 1.1 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -2.9% | 11.2% | -- | -- | -- | -- | -- | -1.9% |
| Dividend Yield | 0.0% | 0.0% | -- | -- | -- | -- | -- | 0.5% |
| Total Returns | -2.9% | 11.2% | -- | -- | -- | -- | -- | -1.4% | Ann. Volatility | 20.4% | 19.8% | -- | -- | -- | -- | -- | 19.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.78 | 24% |
| MSCI EAFE | 0.85 | 38% |
| MSCI Emg Mkts | 0.50 | 22% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.6% |
| Avg. Bid/Ask (% of price) | 0.55% |
Technical Indicators
| 30d moving avg. (EMA) | $24.60 |
| Relative strength (RSI) | 49 |
| MACD/Signal | 0.02/-0.04 |
| Bollinger Bands (Upper/Lower) | $25.35/$23.81 |
| Short interest (% of AUM) | 3.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. THNR |
Expenses vs. THNR |
ALTAR Score™ vs. THNR |
|---|---|---|---|---|
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 59.5% | 0 bp | -0.3% |
| MEDX | Horizon Kinetics Medical ETF | 35.0% | +26 bp | -4.8% |
| PPH | VanEck Pharmaceutical ETF | 31.6% | -23 bp | +1.7% |
| HRTS | Tema Heart & Health ETF | 29.6% | +16 bp | -3.0% |
| XLV | Health Care Select Sector SPDR | 28.7% | -51 bp | +0.9% |
| IYH | iShares U.S. Healthcare ETF | 28.5% | -19 bp | +0.2% |
| IXJ | iShares Global Healthcare ETF | 27.9% | -17 bp | +0.7% |
| VHT | Vanguard Health Care ETF | 27.7% | -50 bp | -0.6% |
| FHLC | Fidelity MSCI Health Care Index ETF | 27.5% | -51 bp | -0.4% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 27.0% | +1 bp | +1.2% |
Risk and Returns: THNR vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/14/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
6.3%
ALTAR SCORE™
78th
PERCENTILE
OVERWEIGHT
ETFRC RATING
There are 585 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. THNR's ALTAR Score™ is approximately 0.8 standard
deviations above the category average. This places THNR in the 78th percentile
among funds in the category.
Sell-Side Consensus
$29.73
PRICE TARGET
+18.8%
UPSIDE